New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 7, 2013
18:07 EDTCVS, AMGN, VZSEC probes Ernst & Young on lobbying issue, Reuters says
The SEC's enforcement division and its Office of the Chief Accountant are looking in to a report that Washington Council Ernst & Young was registered as a lobbyist for several corporate audit clients including Amgen (AMGN), CVS Caremark (CVS) and Verizon Communications (VZ), says Reuters, citing people familiar with the matter. Reference Link
News For AMGN;CVS;VZ From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 30, 2015
07:03 EDTVZVerizon management to meet with Canaccord
Subscribe for More Information
November 25, 2015
16:01 EDTAMGNAmgen submits Biologics License Application to FDA for ABP 501
Subscribe for More Information
November 24, 2015
05:42 EDTAMGNAmgen announces EU approval of Blincyto
Subscribe for More Information
November 23, 2015
14:10 EDTAMGN, CVSAmgen's PCSK9 inhibitor Repatha gets exclusive deal with CVS
Subscribe for More Information
09:21 EDTCVSConsolidated Tomoka disposes non-core income property for about $5.4M
Subscribe for More Information
November 22, 2015
15:03 EDTAMGNMerck reports multiple data sets from Keytruda combination studies
Subscribe for More Information
November 19, 2015
16:06 EDTAMGNAmgen's Kyprolis approved for multuple myeloma by European commission
Amgen announced the European Commission granted marketing authorization for Kyprolis in combination with lenalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. The EC approved Kyprolis based on data from the pivotal Phase 3 ASPIRE trial. The study showed that patients treated with Kyprolis in combination with lenalidomide and dexamethasone had increased median time to progressive disease or death by 8.7 months compared to patients treated with lenalidomide and dexamethasone. Approval from the EC grants a centralized marketing authorization with unified labeling in the 28 countries that are members of the EU. Norway, Iceland and Liechtenstein, as members of the European Economic Area, will take corresponding decisions on the basis of the decision of the EC. Amgen plans to submit data from the Phase 3 ENDEAVOR trial for potential authorization of Kyprolis in combination with dexamethasone in the EU. This data also serves as the basis of the supplemental New Drug Application of Kyprolis in combination with dexamethasone for patients with relapsed multiple myeloma, which has been accepted for priority review by the FDA.
November 18, 2015
15:40 EDTCVSCongressman says U.S. may need look at pharmacy competition, dealReporter says
Subscribe for More Information
11:33 EDTVZSprint announces launch of LTE Plus network
In celebration of the launch of its new LTE Plus network, Sprint (S) is introducing the biggest wireless offer in U.S. history - 50% off the price of most Verizon (VZ), AT&T (T) and T-Mobile (TMUS) rate plans, the company says. New customers can sign up for this offer nationwide Nov. 20 through Jan. 7, 2016. LTE Plus, available today in 77 major markets, takes advantage of Sprint's rich triband spectrum portfolio, and it uses some of the world's most advanced technologies in wireless, such as carrier aggregation and antenna beamforming. Customers who switch get 50 percent off most current rate plan prices from their current carrier. AT&T, T-Mobile and Verizon customers switching to Sprint also can take advantage of iPhone Forever, where they are eligible to upgrade every time a new iPhone launches. Customers must port one line, and can add up to 9 additional lines on the account. Customers must choose from the 50 percent off rate plans available from their current carrier. Cricket and MetroPCS customers also can switch and save 50 percent off their parent company's postpaid rates. 50 percent off pricing remains valid until Jan. 8, 2018, for activations between Nov. 20, 2015, and Jan. 7, 2016.
11:01 EDTCVSTarget says working with CVS team to secure regulatory approval for deal
Target (TGT) says "pleased" with progress to date of CVS (CVS) deal.
November 17, 2015
10:17 EDTCVSHouse Judiciary Committee to hold a hearing
The Subcommittee on Regulatory Reform, Commercial and Antitrust Law holds a hearing entitled, "The State of Competition in the Pharmacy Benefit Manager and Pharmacy Marketplaces" with Vice President Bricker of Express Scripts and Senior Vice President Pons of CVS Health on November 17 at 3 pm. Webcast Link

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use